Session Tracks

This track focuses on the latest innovations in utilizing yeast for drug development, highlighting case studies and breakthroughs in therapeutic applications. Participants will explore the integration of yeast systems in the pharmaceutical pipeline, from discovery to clinical applications.

This session will delve into the strategies and methodologies employed in the metabolic engineering of yeast to enhance the production of biopharmaceuticals. Discussions will include optimizing metabolic pathways to improve yield and efficiency in therapeutic protein production.

This track examines the various protein expression systems harnessed in yeast, focusing on their advantages and limitations in biopharmaceutical production. Participants will share insights on optimizing expression conditions and enhancing protein yield.

This session will explore the discovery and characterization of bioactive compounds derived from yeast, emphasizing their therapeutic potential. Researchers will present findings on the applications of these compounds in drug development and health care.

This track will address the methodologies and technologies for the production of recombinant proteins using yeast as a host. Participants will discuss challenges and solutions in scaling up production for therapeutic applications.

This session focuses on the role of yeast in enzyme production, particularly in the context of pharmaceutical biotechnology. Discussions will cover enzyme engineering, applications in drug synthesis, and the impact on bioprocess efficiency.

This track will highlight the use of yeast as a platform for therapeutic protein engineering, showcasing innovative approaches to enhance protein stability and functionality. Researchers will discuss case studies demonstrating successful engineering outcomes.

This session will explore the potential of yeast systems in the production of vaccines, focusing on the advantages of yeast as a safe and effective platform. Participants will share recent advancements and challenges in yeast-based vaccine development.

This track will cover the entire journey of biopharmaceuticals produced in yeast cell factories, from initial design to market readiness. Discussions will include regulatory considerations, quality control, and commercialization strategies.

This session will focus on the use of yeast models in drug screening processes, highlighting their utility in high-throughput screening and lead identification. Participants will discuss innovative approaches to enhance the predictive power of yeast models.

This track will explore the intersection of synthetic biology and yeast biotechnology, emphasizing the design of novel yeast strains for pharmaceutical applications. Researchers will present their findings on synthetic circuits and engineered pathways for drug production.